Novocure Stock Price, News & Analysis

Novocure (NVCR) reported strong Q2 2024 financial results, with net revenues of $150.4 million, up 19% year-over-year. The company had 3,963 active patients on therapy as of June 30, 2024, an 11% increase from the previous year. Key highlights include:

- Successful launch in France and improved U.S. approval rates
- Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer
- 1,634 prescriptions received, up 5% year-over-year
- Gross margin of 77%
- Net loss of $33.4 million with loss per share of $0.31
- Cash, cash equivalents, and short-term investments of $951.2 million

Novocure continues to focus on growing its commercial business in glioblastoma, launching in non-small cell lung cancer, and advancing its clinical and product development pipelines.

CereVasc, a clinical-stage medical device company, has appointed Shlomi Nachman and Timothy Scannell to its Board of Directors, effective July 11, 2024. Nachman, former Company Group Chairman at Johnson & Johnson's Medical Devices sector, brings over 25 years of industry experience. Scannell, former President and COO of Stryker , has more than 30 years of leadership experience in medical technology.

Dan Levangie, CereVasc's Chairman and CEO, expressed excitement about leveraging their expertise to bring the eShunt System to market. Both appointees have extensive backgrounds in medical devices and neurovascular fields, with Nachman's experience in cardiovascular solutions and Scannell's success in MedSurg & Neurotechnology businesses.

Novocure (NASDAQ: NVCR) will release its financial results for the second quarter of 2024 on July 25, 2024, before the U.S. markets open. A conference call and webcast are scheduled for the same day at 8:00 a.m. EDT to discuss the results. The webcast and accompanying slides will be accessible via the Investor Relations page on Novocure's website and will remain available for two weeks post-call.

Novocure (NASDAQ: NVCR) announced that the METIS Phase 3 clinical trial met its primary endpoint, significantly delaying intracranial progression in patients with brain metastases from non-small cell lung cancer (NSCLC) using Tumor Treating Fields (TTFields) therapy. The trial demonstrated a median time to intracranial progression of 21.9 months for patients treated with TTFields therapy and supportive care, compared to 11.3 months for those with supportive care alone. Quality of life deterioration-free survival was also notably prolonged in the TTFields group, with no evidence of worsening cognitive function. The data will be presented at the 2024 ASCO Annual Meeting. Key secondary endpoints did not achieve statistical significance, with median overall survival at 11.3 months for the TTFields group versus 10.6 months for supportive care alone. Novocure plans to publish these findings and submit them to regulatory authorities.

Novocure (NASDAQ: NVCR) has announced results from the TIGER study, which investigated the use of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) in Germany. The study, conducted from August 2017 to November 2019, included 429 patients and is the largest prospective, non-interventional study of TTFields therapy to date. Key findings indicate a median overall survival of 19.6 months and a median progression-free survival of 10.2 months. The therapy was well tolerated with no increase in systemic toxicity. One-year, two-year, three-year, and four-year survival rates were 79.2%, 42.4%, 31.5%, and 27.7%, respectively. These results align with previous phase 3 EF-14 clinical trial outcomes. The data will be presented at the 2024 American Society of Clinical Oncology Annual Meeting.

Novocure (NASDAQ: NVCR) secured a new $400 million multi-tranche non-dilutive debt financing from Pharmakon Advisors, LP. The facility will be available in four tranches, with the first $100 million issued at closing and the rest to follow by 2026. The funds will support working capital needs for the anticipated launch in non-small cell lung cancer and settle Novocure’s convertible notes. The partnership with Pharmakon strengthens Novocure’s cash position and balance sheet, providing financial stability for future growth.

Novocure (NASDAQ: NVCR) reported strong financial results for the first quarter of 2024 with total net revenues of $138.5 million, up 13% year-over-year. The company had 3,845 active patients on therapy as of March 31, 2024. The METIS Phase 3 clinical trial met its primary endpoint and will be presented at ASCO 2024. Novocure also completed a successful Day-100 meeting with the FDA for the LUNAR PMA application.